Skip to content
Tuesday 28 July 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
City PM

European business, markets and politics

FTSE 100
10,778.74
-0.03%
DAX
25,455.32
+0.37%
CAC 40
8,457.54
+0.61%
STOXX 50
6,299.15
+0.27%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Monday 17 January 2022 7:52 am  |  Updated:  Monday 17 January 2022 7:54 am

Unilever offer for GSK consumer arm is short by £5bn say analysts

By: Lily Russell-Jones

Add as a preferred source on Google
The 2019 Concordia Annual Summit - Day 2
Under the leadership of chief executive Alan Jope, Unilever has made three rejected offers for GSK's consumer goods business (Photo by Riccardo Savi/Getty Images for Concordia Summit)

Unilever’s rejected £50bn offer for Glaxo Smith Kline’s (GSK) consumer business falls short according to market analysts.

Marmite maker Unilever has had three unsolicited offers rebuffed by GSK including a bid made last month which comprised of £41.7bn in cash and £8.3bn in company shares.

Analysts have questioned the financial reasoning behind Unilever’s bid with experts at broker Jefferies estimating that Unilever may have to pay £55bn for the division, a multiple of 18.5 times the companies forecast earnings before tax the Times first reported.

Martin Deboo at Jefferies said Unilever would be forced to tap investors to raise the additional £14bn in cash needed to secure the sale or borrow and sell assets.

“We would expect disclosure of Unilever’s approach to encourage other over-the-counter participants like P&G and Reckitt to reach for their slide rules, as well as perhaps Nestle,” Mr Deboo said in comments to the Telegraph. “Any auction would be a test of Unilever’s resolve and already-stretching deal economics.”

In an update issued today, GSK said that the £50bn bid undervalued its consumer goods business which is due to be spun off from the wider company later this year. The company said: “the Board of GSK unanimously concluded that the proposals were not in the best interests of GSK shareholders as they fundamentally undervalued the Consumer Healthcare business and its future prospects.”

Unilever today defended its offer for GSK’s consumer business which is co-owned by drugs giant Pfizer and makes Panadol painkillers and Aquafresh toothpaste.

“GSK Consumer Healthcare would be a strong strategic fit,” the company announced in a trading update today.

“We believe that this would be an attractive and synergistic combination for the shareholders of Unilever, which would also deliver value and certainty for the shareholders of GSK and Pfizer,” the statement continued, noting that 45 per cent of GSK Consumer Healthcare is in Oral Care and Virtual Memory Systems – categories in which Unilever already has a presence.

Read more: Unilever makes £50bn bid for GSK’s consumer business

Read more

Unilever turns to ‘avocado mayonnaise’ as food weighs on profit ahead of spin-off

Hellmanns Real Mayonnaise jar in a refrigerator with fresh vegetables like tomatoes, lettuce, and onions

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Markets & Economics
  • News

Categories

  • Business

Trending Articles

  • Big Four’s AIM exodus accelerates as mid-tier firms seize mandates

  • FTSE 100 firm agrees £5.7bn takeover in latest private equity swoop

  • Burnham backs plan to pump £1bn pension funds into start-ups

  • Scotland’s tax hike may have backfired as receipt falls

  • As it happened: Stocks rise; oil falls after Trump pauses Iran strikes

More from City PM

  • Unilever turns to ‘avocado mayonnaise’ as food weighs on profit ahead of spin-off

    Retail
    Hellmanns Real Mayonnaise jar in a refrigerator with fresh vegetables like tomatoes, lettuce, and onions
  • Terry Smith dubs weight-loss giant Novo Nordisk ‘investment disaster’

    Investing
    Terry Smith, founder of Fundsmith, speaking at a business conference, wearing a suit and tie, with a focused expression.
  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    Business Wire
  • Jefferies Financial Group Inc. Announces Pricing of €850,000,000 4.500% Senior Notes Due 2033

    Business Wire
  • Prologis tables ‘best and final’ £14bn offer for Segro

    Property
    London Stock Exchange interior with a digital display showing LON.STK.EXCH and traders walking past.
  • ‘We are going to run out’: Mitie marks eleventh mega takeover of 2026

    Markets
    The FTSE 100 enjoyed a 3-year record rally in the third quarter.
  • FTSE 100 Live: Barclays launches £1bn buyback; oil drops to $90 but Trump warns ‘powerful’ return to war

    Markets
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • FTSE 100 property giant Segro rejects £13.5bn Prologis bid

    Property
    David Sleath, Chief Executive Officer, delivering a speech at a business conference with a focused expression.
CityPM

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About City PM
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 City PM Ltd · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook